After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NYSE-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Arcus Biosciences Inc is $2.95B. A total of 1.67 million shares were traded on the day, compared to an average of 1.84M shares.
In the most recent transaction, Robert C. Goeltz II bought 6,552 shares of RCUS for 23.38 per share on Dec 31 ’25. In a previous transaction on Dec 16 ’25, Tang Carolyn C. sold 7,658 shares at 21.88 per share. RCUS shares that General Counsel owns now total 131,544.
Among the insiders who sold shares, Tang Carolyn C. disposed of 6,810 shares on Dec 17 ’25 at a per-share price of $22.16. This resulted in the General Counsel holding 124,734 shares of RCUS after the transaction. In another insider transaction, Markus Richard sold 5,052 shares at $21.88 per share on Dec 16 ’25. Company shares held by the Chief Medical Officer now total 70,141.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RCUS has a high of $26.40 and a low of $6.50.
As of this writing, RCUS has an earnings estimate of -$1.08 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$1.0 per share and a lower estimate of -$1.11. The company reported an EPS of -$1.03 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RCUS’s latest balance sheet shows that the firm has $499.00M in Cash & Short Term Investments as of fiscal 2021. There were $116.89M in debt and $166.00M in liabilities at the time. Its Book Value Per Share was $4.07, while its Total Shareholder’s Equity was $842.00M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RCUS is Buy with a score of 4.54.
